ReviewJournal of pharmacology & pharmacotherapeutics2013
Clinical and economic burden of adverse drug reactions.
Review in Journal of pharmacology & pharmacotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 241 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
241 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies.PharmacoEconomics - open · 2026Pooled it
- Machine learning methods for predicting adverse drug events: A systematic review.British journal of clinical pharmacology · 2026Pooled it
- Hospital admissions due to adverse drug reactions and adverse drug events in older adults: a systematic review.Age and ageing · 2025Pooled it
- Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage.European journal of clinical pharmacology · 2022Pooled it
- The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review.Frontiers in genetics · 2021Pooled it
- Nurses' Knowledge, Attitudes, and Practice in Relation to Pharmacovigilance and Adverse Drug Reaction Reporting: A Systematic Review.BioMed research international · 2021Pooled it
- Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review.PloS one · 2019Pooled it
- Epidemiology of self-medication in Ethiopia: a systematic review and meta-analysis of observational studies.BMC pharmacology & toxicology · 2018Pooled it
- Trial
- Positive social modeling attenuates nocebo side effects.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2025Trial
- Impact of medication nonadherence and drug-drug interaction testing on the management of primary care patients with polypharmacy: a randomized controlled trial.BMC medicine · 2024Trial
- Prospective adverse event risk evaluation in clinical trials.Health care management science · 2022Trial
- Homology-Based Variant-Effect Predictors Break Down on Cytochrome P450 Pharmacogenes.bioRxiv : the preprint server for biology · 2026Article
- Polypharmacy and adverse drug reactions among hospitalised children: determinants and clinical and economic impact in a multicentre prospective cohort and nested matched case-control study in Northwest Ethiopia.BMJ paediatrics open · 2026Article
- Practice, knowledge and attitude of physicians and pharmacists towards the spontaneous reporting system of adverse drug reactions in Switzerland.British journal of clinical pharmacology · 2026Article
- Assessment of drug-related problems and associated factors among patients with chronic obstructive pulmonary disease in Dailekh, Nepal: a cross-sectional study.Scientific reports · 2026Article
- Generative Artificial Intelligence-Empowered Virtual Evolution of Enzyme with the VERnet Model.ACS catalysis · 2026Article
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
- Characterising prescribing cascades in older community-dwelling adults attending general practice in The Netherlands: a retrospective cohort study.BMC primary care · 2026Article
- Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions.AAPS PharmSciTech · 2026Review
181 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions (ADRs) are unwanted drug effects that have considerable economic as well as clinical costs as they often lead to hospital admission, prolongation of hospital stay and emergency department visits. Randomized controlled trials (RCTs) are the main premarketing methods used to detect and quantify ADRs but these have several limitations, such as limited study sample size and limited heterogeneity due to the exclusion of the frailest patients. In addition, ADRs due to inappropriate medication use occur often in the real world of clinical practice but not in RCTs. Postmarketing drug safety monitoring through pharmacovigilance activities, including mining of spontaneous reporting and carrying out observational prospective cohort or retrospective database studies, allow longer follow-up periods of patients with a much wider range of characteristics, providing valuable means for ADR detection, quantification and where possible reduction, reducing healthcare costs in the process. Overall, pharmacovigilance is aimed at identifying drug safety signals as early as possible, thus minimizing potential clinical and economic consequences of ADRs. The goal of this review is to explore the epidemiology and the costs of ADRs in routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.